Entera Bio Ltd. Graham Net Nets

Graham Net Nets of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Graham Net Nets growth rates and interactive chart. Net current asset value divided by market cap. Calculated as current assets minus total liabilities divided by market cap.

Highlights and Quick Summary

Current Graham Net Nets of Entera Bio Ltd. is 0.42 (as of December 30, 2019)
  • Graham Net Nets for the quarter ending June 29, 2020 was 0.19 (a -23.13% decrease compared to previous quarter)
  • Year-over-year quarterly Graham Net Nets increased by 90.24%
  • Annual Graham Net Nets for 2019 was 0.42 (a 116.21% increase from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Graham Net Nets of Entera Bio Ltd.

Most recent Graham Net Netsof ENTX including historical data for past 10 years.

Interactive Chart of Graham Net Nets of Entera Bio Ltd.

Entera Bio Ltd. Graham Net Nets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.19 0.24
2019 0.42 0.1 0.13 0.42
2018 0.19 0.19

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.